source
- FDA advisory panel lifts restrictions on six wellness peptidesThe FDA's advisory committee concluded its two-day meeting by voting to remove the existing limits on six widely used health and wellness peptides. Committee members said the vote overrode earlier…
- MapLight’s schizophrenia drug misses primary endpoint in Phase 2, shares tumble over 60%MapLight Therapeutics reported results from a mid‑stage Phase 2 trial of its experimental schizophrenia therapy. The study evaluated a once‑daily dosing regimen and failed to meet the predefined p…